Table 4.
NET marker levels according to adverse clinical events after 12-month follow-up.
| Adverse clinical event - | Adverse clinical event + | p | |
|---|---|---|---|
| dsDNA (ng/ml) | |||
| Before PCI | 450 (385, 538) | 506 (415, 745) | 0.022 |
| After PCI | 433 (380, 506) | 499 (387, 630) | 0.037 |
| Day 1 | 360 (327, 406) | 402 (376, 436) | 0.005 |
| After 4 months | 338 (310, 371) | 349 (318, 368) | 0.833 |
| MPO-DNA (OD) | |||
| Before PCI | 0.239 (0.205, 0.294) | 0.306 (0.196, 0.359) | 0.210 |
| After PCI | 0.232 (0.203, 0.272) | 0.225 (0.212, 0,254) | 0.454 |
| Day 1 | 0.230 (0.182, 0.341) | 0.274 (0.189, 0.330) | 0.484 |
| After 4 months | 0.195 (0.155, 0.247) | 0.158 (0.140, 0.205) | 0.045 |
Adverse clinical event is defined as a composite of death, myocardial infarction (MI), unscheduled revascularization ≥ 3 months after the index infarction, stroke, or rehospitalization for heart failure. dsDNA: double-stranded deoxyribonucleic acid. MPO-DNA: myeloperoxidase-deoxyribonucleic acid. OD: optical density units. PCI: percutaneous coronary intervention.